May 26, 2023
July 2023 HCPCS Updates – New, Revised and Discontinued HCPCS Codes – Revised
The following information is based on the July 2023 Healthcare Common Procedure Coding System (HCPCS) file. There are several updates that will be effective July 1, 2023. Please keep in mind that the appearance of a HCPCS code is not an indication of coverage by the DME MAC.
This following list contains added HCPCS codes that will be effective July 1, 2023.
HCPCS | DESCRIPTION |
---|---|
J0137 | Injection, acetaminophen (hikma) not therapeutically equivalent to j0131, 10 mg |
J0206 | Injection, allopurinol sodium, 1 mg |
J0216 | Injection, alfentanil hydrochloride, 500 micrograms |
J0457 | Injection, aztreonam, 100 mg |
J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg |
J0736 | Injection, clindamycin phosphate, 300 mg |
J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg |
J1576 | Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg |
J1805 | Injection, esmolol hydrochloride, 10 mg |
J1806 | Injection, esmolol hydrochloride (wg critical care) not therapeutically equivalent to j1805, 10 mg |
J1811 | Insulin (fiasp) for administration through dme (i.e., insulin pump) per 50 units |
J1812 | Insulin (fiasp), per 5 units |
J1813 | Insulin (lyumjev) for administration through dme (i.e., insulin pump) per 50 units |
J1814 | Insulin (lyumjev), per 5 units |
J1836 | Injection, metronidazole, 10 mg |
J1920 | Injection, labetalol hydrochloride, 5 mg |
J1921 | Injection, labetalol hydrochloride (hikma) not therapeutically equivalent to j1820, 5 mg |
J1941 | Injection, furosemide (furoscix), 20 mg |
J1961 | Injection, lenacapavir, 1 mg |
J2249 | Injection, remimazolam, 1 mg |
J2305 | Injection, nitroglycerin, 5 mg |
J2329 | Injection, ublituximab-xiiy, 1mg |
J2371 | Injection, phenylephrine hydrochloride, 20 micrograms |
J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms |
J2427 | Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg |
J2561 | Injection, phenobarbital sodium (sezaby), 1 mg |
J2598 | Injection, vasopressin, 1 unit |
J2599 | Injection, vasopressin (american regent) not therapeutically equivalent to j2598, 1 unit |
J2806 | Injection, sincalide (maia) not therapeutically equivalent to j2805, 5 micrograms |
J9029 | Injection, nadofaragene firadenovec-vncg, per therapeutic dose |
J9056 | Injection, bendamustine hydrochloride (vivimusta), 1 mg |
J9058 | Injection, bendamustine hydrochloride (apotex), 1 mg |
J9059 | Injection, bendamustine hydrochloride (baxter), 1 mg |
J9063 | Injection, mirvetuximab soravtansine-gynx, 1 mg |
J9259 | Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to j9264, 1 mg |
J9322 | Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg |
J9323 | Injection, pemetrexed ditromethamine, 10 mg |
J9347 | Injection, tremelimumab-actl, 1 mg |
J9350 | Injection, mosunetuzumab-axgb, 1 mg |
J9380 | Injection, teclistamab-cqyv, 0.5 mg |
J9381 | Injection, teplizumab-mzwv, 5 mcg |
Q5131 | Injection, adalimumab-aacf (idacio), biosimilar, 20 mg |
The following listing contains discontinued HCPCS codes, along with the cross-walked HCPCS codes (if applicable). Please note, not all discontinued HCPCS codes will have a cross-walked HCPCS code.
HCPCS | DISCONTINUE DATE | CROSSWALK HCPCS CODE |
---|---|---|
J2370 | 6/30/2023 | None |
The following HCPCS Code has description/verbiage changes that will be effective July 1, 2023.
HCPCS | New Description |
---|---|
J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
Publication History
May 26, 2023 | Originally Published |
June 14, 2023 | Revised description of J9323 and removed J9321. |